ArticleJVS-vascular science2026
In vitro characterization and angiogenic potential of quality-and-quantity mononuclear cell-derived extracellular vesicles.
Article in JVS-vascular science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the presence, production rate, and in vitro angiogenic properties of quality-and-quantity culture mononuclear cells-derived extracellular vesicles (QQMNC-EVs). Methods: Peripheral blood from three healthy volunteers was processed into five groups: QQMNC-EVs, QQMNCs, peripheral blood mononuclear cell-derived EVs (PBMNC-EVs), CD34 Results: QQMNC-EVs were identified and met established EVs criteria. QQMNCs produced the highest EVs yield. This was significantly higher than CD34 Conclusions: QQMNC-EVs were successfully identified and showed in vitro angiogenic efficacy, highlighting their potential as a novel therapeutic strategy for patients with no-option chronic limb-threatening ischemia. Clinical Relevance: Extracellular vesicles (EVs) were successfully identified and characterized from QQMNCs and had the highest production rate among the four cell groups: QQMNCs, standard peripheral blood mononuclear cells, CD34
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.